MARRIOTT RIVE GAUCHE & CONFERENCE CENTER, PARIS, FRANCE

Thinner and thinner: does the next generation endograft compromise durability?

Philippe Cuypers, MD, PhD Catharina Hospital, Eindhoven, The Netherlands

JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG

## Disclosure

Speaker name:

Philippe Cuypers

□ I have the following potential conflicts of interest to report:

Other(s): Educational Grant Medtronic, Cook



# "Thinner and thinner" ~ "Less is more"

# 'view that a minimalistic approach is more effective or more appreciated'

Wikipedia

**JANUARY 25-27 2018** MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG

## "Less is more"







## Less is more?

What are the possible <u>benefits</u> of lower profile introducer systems?

- Treat more patients?
- Make current EVAR procedures safer?
- More and safer percutaneous access?
- Marketing tool?

JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG

# Treat more patients?

• Unsuitable: 10-40 %

- Reasons for unsuitability:
  - Neck issues: 70-80 %
  - Access issues: 20-30 %
- Unsuitable because of access: 5-10%

Simons et al. JVS 2003;38:758-61 Zarins et al. Ann Surg 2000;232:501-7



JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG

# Population dependent unsuitability?


## • Persistent gender difference

- Ulug et al. Lancet 2017 Jun 24;389:2482-2491: systematic review and meta-analysis
- Suitability for EVAR was significantly lower for women (34%) than for men (54%)
- Racial difference
  - Banzic et al. Eur J Vasc Endovasc Surg. 2016 Jun;51(6):783-9
  - Length and diameters differs significantly between Caucasian and Asian population





# Make EVAR procedures safer?



## dreəm

- No major safety issues during first 30 days
- Major concern is reintervention rate






# More and safer percutaneous access?

• Patient comfort and recovery, cost-effectiveness


• Latest closure devices can easily deal with large profile devices

JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG



JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG

# Marketing tool?







# What are the possible risks of lower profile introducer systems?

## 1. Manufacturer: inadequate device

2. Physicians: treat wrong patients



JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG

# 1. Device durability: how to reduce profile?

- Thinner graft material
- Change structure/thickness of stents
- Less markers
- Tri-fab construction
- Innovative design to reduce profile (Ovation, Nellix)





# Potential drawbacks of low profile


Recent experience with profile < 18 Fr:


- Zenith LP, Cook: 16-17 Fr
- Incraft, Cordis: 14 Fr
- Endurant EVO, Medtronic: 15 Fr





# 2. Allow physicians to perform EVAR in patients who should not have EVAR at all








JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG

# 5 yrs ENGAGE: reason for secondary interventions





JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG

# Comparison of midterm results for the Talent and Endurant stent graft

Yannick W. 't Mannetje, MD,<sup>a,b</sup> Philippe W. M. Cuypers, MD, PhD,<sup>a</sup> Ben R. Saleem, MD,<sup>a</sup> Aron S. Bode, MD, PhD,<sup>a</sup> Joep A. W. Teijink, MD, PhD,<sup>a,b</sup> and Marc R. H. M. van Sambeek, MD, PhD,<sup>a</sup> *Eindhoven and Maastricht, The Netherlands* 

J Vasc Surg 2017;66:735-42

Variables	Talent (n = 90)	Endurant (n = 131)	<i>P</i> value
Age, years	73.0 ± 7.4	72.6 ± 8.0	.680
Male	93.3 (84/90)	85.5 (112/131)	.071
ASA class			.312
1	1.1 (1/88)	6.1 (8/131)	
2	68.2 (60/88)	66.4 (87/131)	
3	26.1 (23/88)	24.4 (32/131)	
4	4.5 (4/88)	3.1 (4/131)	


JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG

Variable	Talent (n = 55)	Endurant (n = 118)	<i>P</i> value <sup>®</sup>
Proximal neck length, mm	39 ± 12.8	32 ± 13.7	.183
Proximal neck diameter, mm	23 ± 2.6	23 ± 3.2	.505
Distal neck diameter, mm	24 ± 3.0	$24 \pm 3.7$	.652
>32 mm (n)	1	2	
Suprarenal angulation, degrees	20 (14-28)	20 (14-35)	.565
Infrarenal angulation, degrees	48 ± 21.1	47 ± 25.3	.699
AAA diameter, mm	58 (54-65)	57 (53-62)	.354
Right CIA max, <sup>b</sup> mm	17 (14-21)	16 (13-19)	.047
Left CIA max, <sup>b</sup> mm	15 (13-19)	15 (13-18)	.141
Right EIA, mm	9 (9-10)	9 (8-10)	.089
Left EIA, mm	10 (8-11)	9 (8-10)	.199
Infrarenal neck outside IFU <sup>c</sup> (n/N)	18.2% (10/55)	16.1% (19/118)	.733





## Freedom from secondary interventions



**JANUARY 25-27 2018** MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG

Variable	Talent patients (interventions)	Endurant patients (interventions)	P value
Secondary interventions	28.4% (25/88)	23.8% (30/126)	.449
Independent interventions			
Type la	10 (12)	6 (6)	.071
Type Ib	2 (2)	3 (3)	1.000
Type II	0	4 (4)	.145
Type III	1 (1)	3 (3)	.645
Graft migration	7 (8)	O (O)	.002
Limb dislocation	2 (2)	1 (1)	.570
Occlusion	3 (3)	7 (7)	.531
Stenosis	O (O)	6 (10)	.044
Marginal sealing	3 (3)	5 (5)	1.000
Other	7 (9)	1 (1)	
Intervention for proximal neck <sup>a</sup>	18.2% (16/88)	4.8% (6/126)	.001
Intervention for iliac limb <sup>b</sup>	3.4% (3/88)	7.9% (10/126)	.172

## Endurant +

Talent +

# Discussion

 Priority for physicians and patients is not treating "more" but treating "better"

 Longterm durability and further reduction of secondary intervention should be higher priority than reducing introducer profile

# Conclusion

• Latter generation endografts do perform better in terms of durability, especially for proximal neck sealing

- Caution for profile < 18 Fr:
  - Physicians are tempted for use in patients who should not have EVAR at all
  - So far, manufacturers are not ready to guarantee durability